Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Market Cap: N/A
Industry: Pharmaceuticals & Biotechnology
ISIN: CNE1000062J1

HKD

438.60

21 (5.03%)

Dec 12

HKG

Click here to see other stocks

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

SciClone Pharmaceuticals (Holdings) Ltd.

Livzon Pharmaceutical Group, Inc.

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.

Ocumension Therapeutics

Shandong Boan Biotechnology Co., Ltd.

Cutia Therapeutics

Lepu Biopharma Co., Ltd.

RemeGen Co., Ltd.

Everest Medicines Ltd.

InnoCare Pharma Ltd.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Why is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ?

Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%

Poor long term growth as Operating profit has grown by an annual rate -413.15% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -18.01
NO KEY NEGATIVE TRIGGERS

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 130.84%, its profits have risen by 47%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

130.84%

2.35

62.09%

Hang Seng Hong Kong

27.36%

1.06

25.88%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

204.90%

EBIT Growth (5y)

-413.15%

EBIT to Interest (avg)

-18.01

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.91

Sales to Capital Employed (avg)

0.06

Tax Ratio

87.15%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

20.23

EV to EBIT

-225.37

EV to EBITDA

-335.43

EV to Capital Employed

205.84

EV to Sales

32.47

PEG Ratio

Dividend Yield

ROCE (Latest)

-91.33%

ROE (Latest)

-8.88%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend